

FOR IMMEDIATE RELEASE

Contact:

Sasha Latypova

(585) 295 7610 X103

sasha.latypova@icardiac.com

## **iCardiac Reports Record Revenue Growth**

### **Year-Over-Year Revenues Grow by 76% and Cardiac Safety Revenues Increase Seven Fold**

Rochester, New York – August 10, 2010 – iCardiac Technologies, Inc., a provider of next generation cardiac core lab services, announced today that the company’s annual revenues for the period ended June 30<sup>th</sup>, 2010 increased by 76% compared to the year-over-year period. Excluding large biomarker development projects completed in fiscal 2009, the revenues from pharmaceutical cardiac safety studies increased seven fold for fiscal year 2010 as compared to fiscal year 2009.

“The revenue growth in 2010 represents the fastest revenue growth experienced in the history of the company and reflects the rapid market adoption of iCardiac’s unique Highly Automated QT<sup>sm</sup> and Dynamic QT beat-to-beat<sup>sm</sup> solutions,” said iCardiac’s CEO Mikael Totterman. “Additionally, iCardiac’s ability to reliably meet the rapidly increasing customer demand is a testament to the highly scalable technology infrastructure developed and perfected over the past decade.”

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives and high cost of the “gold standard” manual or semi-automated QT measurements has led to efforts toward providing more advanced cardiac safety analytics.

#### **About iCardiac Technologies**

iCardiac Technologies, Inc., provides drug development companies worldwide with the complete range of next generation cardiac safety core lab services. Its team of cardiac safety experts collectively bring over 100 years of cardiology, electrophysiology, drug development, regulatory and academic experience. The iCardiac team pioneered the field of Highly Automated QT evaluation as well as controlling for autonomic nervous system effects on the QT interval, a phenomenon estimated to produce false-positive results in conventional QT studies for as many as 25% of all molecules currently in clinical development. iCardiac’s services are supported by the COMPAS technology platform which maximizes the precision and decreases the cost of cardiac safety assessment from First-in-Human studies to Phase III studies. This suite of tools, which complies with the FDA’s ICH E14 QT/QTc guidance for Through QT Studies (TQT), was originally

developed and validated at the University of Rochester's Heart Research Follow Up Program (HRFUP), as well as in Pfizer's Research and Development programs. iCardiac's analytics have been used for over a decade in support of clinical trials. For more information, visit [www.icardiac.com](http://www.icardiac.com).